EU watchdog reviews Moderna jab for Omicron
Stay tunned with 24 News HD Android App
It is the second modified jab that the European Medicines Agency (EMA) has begun studying for approval after Pfizer/BioNTech's earlier this week.
The so-called rolling review will continue until there are enough data for a formal application to market the Moderna jab, which is known in Europe as Spikevax, within the 27-nation bloc, the EMA said.
Fears are mounting that coronavirus variants are making a comeback, with infection levels in Britain and the Netherlands rising recently.
Pfizer/BioNTech said earlier this week that their adapted jab would target "Omicron and its subvariants."